已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies

医学 美罗华 内科学 自身免疫性溶血性贫血 贫血 胃肠病学 淋巴瘤
作者
Quitterie Reynaud,I. Durieu,Marine Dutertre,Stanislas Ledochowski,Stéphane Durupt,Anne‐Sophie Michallet,Denis Vital-Durand,Jean‐Christophe Lega
出处
期刊:Autoimmunity Reviews [Elsevier BV]
卷期号:14 (4): 304-313 被引量:135
标识
DOI:10.1016/j.autrev.2014.11.014
摘要

This study aims to evaluate the response to rituximab (RTX) treatment in auto-immune hemolytic anemia (AIHA) patients. Studies were selected from MEDLINE up to March 2014. Two investigators independently extracted data on study design, patient characteristics, clinical features (AIHA type, disease duration, previous treatments), dose-schedule of rituximab, duration of treatment follow-up, and toxicities. Pooled overall response rate (ORR) and complete response (CR) rates were evaluated to determine RTX efficacy and toxicity by calculating the weighted mean proportion with fixed or random-effects models in case of heterogeneity (p < 0.1 or I2 > 50%). Twenty-one studies encompassing 409 patients were included in the meta-analysis. The characteristics of the entire analyzed cohort reported were as follows: mean male proportion: 43%, mean age: 50 years, splenectomized patients range: 0–50%. Warm AIHA, primary AIHA and adults were mostly represented. With the random-effect model, the overall response rate (ORR) was 73% (95% CI 64–81%, 20 studies encompassing 402 patients). CR rate was 37% (95% CI 26–49%, 20 studies including 397 patients). The ORRs were close to 70% for warm AIHA (79%, 95% CI 60–90%, 11 studies, 154 patients), primary AIHA (67%, 95% CI 49–81%, 10 studies, 161 patients), and secondary AIHA (72%, 95% CI 60–82%, 8 studies, 66 patients). The ORR was 57% (95% CI 47–66%, 6 studies, 109 patients) for cold agglutinin disease (CAD). The CR rate was 42% (95% CI 27–58%, 11 studies, 154 patients) for warm AHAI, 32% (95% CI 17–51%, 11 studies, 176 patients) for primary AIHA, 46% (95% CI 30–62%, 9 studies, 87 patients) for secondary AIHA and only 21% (95% CI 6–51%, 7 studies, 118 patients) for CAD. Definitive response rates were evaluated during follow-up. CR rate was the highest within 2 to 4 months after RTX (13 studies, 203 patients, CR = 70% [57–80%]). As for toxicities, 38 adverse events in 364 patients were noted (14% (95% CI 9-21%)). Sixteen events were infusion-linked side effects, mostly chills and fever, whereas twenty-two were severe. Only one opportunistic Pneumocystis jiroveci pneumonia was reported. Seventeen patients out of 364 (4.6%) died during follow-up. In univariate mixed-effect meta-regressions, ORR and CR were significantly associated with warm AIHA (p = 0.002) and mean age (p < 0.001), and marginally associated with disease type (p = 0.06 and 0.005, respectively). Rituximab seems to be a safe and effective therapy for AIHA in this meta-analysis of observational studies. The authors suggest that it could be used at an earlier point in therapy, before more toxic immunosuppressive drugs, or in place of splenectomy in some cases.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
漂亮的战斗机完成签到 ,获得积分10
刚刚
XXM完成签到 ,获得积分10
刚刚
1秒前
畅快访蕊发布了新的文献求助10
5秒前
汉堡包的应助被shamo采纳,获得10
7秒前
sun完成签到 ,获得积分10
8秒前
9秒前
Waitcy发布了新的文献求助10
12秒前
畅快访蕊完成签到,获得积分20
13秒前
热心丹南完成签到,获得积分10
16秒前
刻苦绿蕊完成签到,获得积分10
18秒前
FashionBoy的应助被典雅的可乐采纳,获得10
18秒前
19秒前
mmy完成签到 ,获得积分0
20秒前
ning完成签到 ,获得积分10
23秒前
stan发布了新的文献求助10
24秒前
酷酷乐双完成签到,获得积分10
24秒前
Xi关闭了Xi的文献求助
26秒前
阿娴完成签到 ,获得积分10
27秒前
27秒前
Hello的应助被u459150采纳,获得10
29秒前
短短急个球完成签到,获得积分0
29秒前
单纯的海完成签到 ,获得积分10
30秒前
30秒前
32秒前
远赴倒悬山完成签到 ,获得积分10
34秒前
爆米花的应助被fuz采纳,获得10
34秒前
moos完成签到 ,获得积分10
34秒前
34秒前
ff完成签到,获得积分10
34秒前
35秒前
36秒前
36秒前
李爱国的应助被anya采纳,获得10
36秒前
淡然绝山发布了新的文献求助30
37秒前
肉松小蛋糕完成签到,获得积分20
37秒前
39秒前
丁丁发布了新的文献求助10
39秒前
40秒前
小冼完成签到 ,获得积分10
42秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194853
求助须知:如何正确求助?哪些是违规求助? 9580631
关于积分的说明 21872074
捐赠科研通 7794509
什么是DOI,文献DOI怎么找? 3437779
关于科研通互助平台的介绍 2561109
邀请新用户注册赠送积分活动 2484488